pauloverdi
01 Aug 2017
Re: Cor Drip drip drip yet no comment from you guys. Any ideas with the share drop ??Paulo
pauloverdi
24 Jul 2017
Re: Cor Down 54p since the beginning of July !! News has been good and brokers recommending !! Only explanation can be that it's being shorted !! Why I don't know especially when news has been quite positive !! Any clues guys ?Kind regardsPaulo
dave297
13 Jul 2017
Re: Update is looking good for 2017/18 Update does look good but what are the chances of AZN trying to poach her for their vacancy .Perhapsctgey would have to buy our company too ?
d gaser
13 Jul 2017
Update is looking good for 2017/18 BTG plc: Annual General MeetingLondon, UK, 13 July 2017: BTG plc (LSE: BTG), the global specialist healthcare company, provides the following update ahead of its Annual General Meeting, which is being held today at 10.30am at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London, EC2M 7SH. At the meeting, the Board will comment on the performance of the Group in the year ended 31 March 2017, as detailed in the results announcement on 16 May 2017, and describe progress made in the current financial year to date. Louise Makin, Chief Executive Officer, commented: "Our strong performance in 2016/17 has continued into the new financial year. We are on track to achieve double-digit product sales growth over the full financial year, driven by growth in our Interventional Medicine business. We reported positive outcomes from two EKOS clinical studies in the first quarter and we anticipate further progress across the portfolio over the full year, including reaching important milestones for Varithena® and the PneumRx® Coils. We will continue to implement our growth strategy, to deliver double-digit annual product sales growth and margin expansion over time whilst investing selectively in innovation and development, commercial and geographic expansion and acquisitions to ensure sustainable long-term value creation." Trading since 1 April 2017 has been in line with the Board's expectations and guidance for the full year is unchanged. There were strong performances from TheraSphere®, the liver cancer treatment, and EKOS®, the blood clot treatment device. Varithena continues to make progress ahead of the publication of new reimbursement codes expected towards the end of the year. The antivenin CroFab® made a good start to the new snakebite season and there was a good performance from Voraxaze®, used to treat methotrexate toxicity in patients with impaired renal function. There was also good operating progress. Positive data were reported from two clinical studies using EKOS®. The OPTALYSE study demonstrated the safety and efficacy of shorter, lower-dose EKOS® therapy for pulmonary embolism, and the ACCESS PTS study demonstrated the safety and efficacy of an EKOS® therapy treatment regimen for post-thrombotic syndrome. A pilot study showed sustained quality of life at regular intervals throughout three months in patients treated with TheraSphere® using IO Loop™, a novel data collection tool that helps patients better engage in their own healthcare and measures quality of life and satisfaction rates across the course of their treatment. In June 2017, the Society of Interventional Oncology and BTG announced their 2017 interventional oncology/immuno-oncology grant recipients. This research grant programme funds initiatives that evaluate how interventional oncology therapies stimulate the immune system and how they might combine with immunotherapy approaches to improve clinical outcomes. Work continues to progress the Premarket Approval application in the US for the PneumRx® Coils, and in Europe coverage/reimbursement determinations continue in Germany and France.
i network
07 Jul 2017
Re: Cor Lending shares for shorting purposes, to me, is an example of derivative trading; which to me is a backhanded way of double entry of the same asset. This is what, in another guise led to the banks crisis some years back. I believe that these derivatives are a danger to the markets, Governemts , if they had a similar practice would never be allowed to get away with it. Often the people who are involved in these black arts are the first to criticise gov't for deficit spanding, which is far better, in that it lacks a veil of deception. Ironically the main recent cause of gov't debt came from bailing out the banks, and in effect the investors using these black arts.Michael
d gaser
07 Jul 2017
Re: Cor Hi Pro take a look at [link] Happy Dave .
Mike Land
06 Jul 2017
Re: Cor I am not sure I agree. Logically you are holding a stock as a long investment in order to make money. You believe the share will go up. A short stock holder simply has the opposite view. He thinks it will go down so invests in the negative ie he shorts the stock. If shorting a stock is wrong so is going long?I agree if stock lending was banned that would make shorting a stock much riskier. But it would not change the underlying market need for buyers AND sellers.
up protherics
06 Jul 2017
Re: Cor dgaserStock lenders are accredited...I am not sure you still can find the list of accredited stock lenders, but as an example ten years ago the list consisted of. A good way to find out is to become a Ctrest/euroclear member.BONYMorgan Stanley etc etcINMO.. stock lending is a double hyprotic standard.If you removed stock lending .. No one could short a stock.. As there are buying in rules for non settlement of trades..So in summary my opinion is that any institution who lends stock out in the knowing belief that it is going to be used for someone to short the stock.( after themselves acquiring the stock on behalf of a pension fund). Is in the very least vile.
dave297
05 Jul 2017
Re: Cor We are heading up & the momentum is with us again , which should continue if the forthcoming trading update remains positive .I may regret reducing my sizeable stake by about 70%( before our SP slid back to recent lows).A large amount of the proceeds went into SKP which has become Vectura & has struggled since the acquisition.History may show that I should have retained my full exposure here
pauloverdi
04 Jul 2017
Re: Cor Share Price !!!Us poor suffering shareholders who continually have to watch the vagaries of the highs and lows of the share price is enough to drive you to the bl**ding hat shop !!!I've arranged a coach to save time and we'll all meet at Brighton Pier and drive directly to the Hat Shop !!!Frustration hampers will be handed out on the day !!!On another observation AAARGH !!!!Ciao Paulo
Mike Land
03 Jul 2017
Re: Cor The trouble with passive investment where you invest in the index is the managers have shares they own not because they wanted that share but because it is in the index. So to make a few basis points of return you loan it out to a shorter.
d gaser
03 Jul 2017
Re: Cor those shorting are GSA Capital Partners LLP 0.60% ª 0.09% since 09-06-2017Macquarie Funds Management Hong Kong Limited 0.50% they took a short on 01-06- 2017But who is supplying the shares to short the stock in the first place as neither own stock ?BE HAPPYDAVE
dave297
23 Jun 2017
Vectura Perhaps our increasing SP & rating will tempt The Dame to buy Vectura to put me out of my misery & increase my decent holding here substantially !
up protherics
17 Jun 2017
Cor Coooore blimey governore apparently some spivs are shorting or snorting the stockhey ho love and kisses from a long term btg hold
d gaser
16 Jun 2017
ACCESS PTS study meet eligibility This is more good news for BTG and our EKOS therapy .BE HAPPYDAVE ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome Bothell, WA, 16 June 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th Annual Scientific Sessions in New Orleans, June 14 to 17. The study found chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can be treated safely and effectively with EKOS® therapy. The ACCESS PTS protocol using EKOS® therapy is now the only treatment regimen proven to significantly reduce the signs and symptoms of PTS and show a significant improvement in quality of life. The ACCESS PTS study is a multicenter prospective single-arm study of 73 patients with iliofemoral DVT, meeting eligibility including a Villalta Score of 8 or greater (Villalta Score measures the signs and symptoms of PTS), and who had failed three months of conservative therapy. Patients were treated with anticoagulation drugs followed by EKOS® therapy with balloon dilatation. The study met its primary efficacy endpoint and showed a significant improvement of Villalta Scores of 34% at 30 days across 77 limbs treated among the 73 patients with a p-value of <0.0001. On average, patients treated in the study experienced a symptom reduction from severe down to borderline mild. The study also showed a 21% improvement in patients' quality of life.1 There was one bleeding incident and one PE - meeting the study's safety endpoint. "ACCESS PTS demonstrates that EKOS® therapy with balloon dilatation is effective and safe in reducing the signs and symptoms of post-thrombotic syndrome for patients suffering from chronic deep vein thrombosis, while improving their quality of life," said lead investigator Dr. Mark Garcia of Vascular & Interventional Associates of Delaware in Wilmington, Delaware. "EKOS® therapy is a useful and important option for physicians treating debilitating chronic DVT and PTS." In addition to Dr. Garcia, the study's authors include Dr. Keith Sterling of Inova Alexandria Hospital; Dr. Michael Jaff of Newton-Wellesley Hospital; Dr. Kenneth Ouriel of Syntactx; Dr. Susan Kahn of Jewish General Hospital; and Dr. Anthony Comerota of Jobst Vascular Institute. "With the ACCESS PTS study, BTG is once again demonstrating our commitment to advancing the treatment of VTE patients. Chronic DVT can be both debilitating and life threatening. Until now, most chronic DVT and PTS sufferers had no other treatment options," said EKOS® Vice President and General Manager Matt Stupfel. "The ACCESS PTS data proves that EKOS® therapy is a safe and effective option for treating chronic DVT. EKOS® is setting the standard for interventional chronic-DVT treatment, getting patients back on their feet and on with their lives." About Chronic Deep Vein ThrombosisDeep Vein Thrombosis (DVT) is a debilitating and potentially life threatening condition. It occurs when a blood clot forms in one of the deep veins in your body, limiting blood flow. It usually occurs in your leg or pelvis, but it can also occur in your arm or chest. If the clot isn't dissolved within a few weeks, it can become a Chronic Deep Vein Thrombosis. When this happens, the blood clot interferes with blood flow and can permanently damage the valves in your veins2 creating a condition call Post-Thrombotic Syndrome (PTS). About 50% of patients with chronic DVT in the upper leg area may develop PTS which can cause disability and negatively impact the quality of life.2,3 Prior to ACCESS PTS, there was no proven treatment option for PTS. About the EkoSonic® Endovascular SystemThe EKOS® system uses ultrasonic waves in combination with clot-dissolving thrombolytic drugs to effectively dissolve clots and restore healthy blood flow. In clinical studies EKOS® therapy has been shown to sp
